AsiaIPEX is a one-stop-shop for players in the IP industry, facilitating IP trade and connection to the IP world. Whether you are a patent owner interested in selling your IP, or a manufacturer looking to buy technologies to upgrade your operation, you will find the portal a useful resource.

Back to search results

Development of combination therapy against influenza pneumonia

Summary

This invention offers a novelcombination therapy for influenza pneumonia. The drugs used in this combinationtherapy targets both neutrophil-induced ARDS and the virus itself, providing ahost of beneficial synergistic effects. According to the invention, a novel combinationtherapy targeting the host response has been used in combination with anantiviral agent, oseltamivir, for the treatment of severe influenza infectionin mice. Based on the findings, dual-treatment significantly enhances thesurvival of mice after lethal influenza challenge, when compared to treatmentof anti-viral alone.

Technology Benefits

Reduced neutrophil influxDecreased vascular leakageDecreased endothelial damageDecreased release of NETsSynergistic therapeutic increases survival in mice

Technology Application

Therapeutictreatment for influenza pneumonia

Detailed Technology Description

None

Country/Region

USA

For more information, please click Here